AC Immune To Host Key Opinion Leader Webinar On Early Diagnosis And Prevention Of Alzheimer’s Disease

• Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST
   

Lausanne, Switzerland, April 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host a key opinion leader (KOL) webinar on early diagnosis and prevention of Alzheimer’s disease on Tuesday, April 18, 2023 at 10:30 AM EDT / 4:30 PM CEST.

Andrea Pfeifer, PhD, AC Immune’s Chief Executive Officer, will begin the webinar with an overview of the company’s strategic direction and expectations for the year before introducing the invited speakers: Kaj Blennow, MD, PhD, of University of Gothenburg and Sahlgrenska University Hospital, and Giovanni Frisoni, MD, of University of Geneva and the Memory Clinic at Geneva University Hospital.

Drs. Blennow and Frisoni will discuss improved techniques and agents in development to detect and monitor Alzheimer’s disease at earlier stages in order to enable the development and use of therapeutic vaccines to delay or even prevent the onset of irreversible clinical symptoms. The discussion will also cover how the availability of biomarkers measurable by brain imaging and in biofluids as clinical endpoints may enable a Precision Medicine approach for agents treating pre-symptomatic patients.

AC Immune’s Chief Scientific Officer, Marie Kosco-Vilbois, PhD, will then present the Company’s integrated Precision Medicine approach for Alzheimer’s disease, which leverages its cutting-edge PET-tracer programs. Johannes Streffer, MD, Chief Medical Officer, will close the formal presentations by discussing AC Immune’s two clinical-stage Alzheimer’s disease vaccines targeting amyloid-beta (ACI-24.060) and phosphorylated Tau (ACI-35.030).

A live Question and Answer session will follow the formal presentations. 

Read the full press release